Global Pharmaceutical Sales Grew 5% to $386 billion; U.S. Share $196 billion
Global
pharmaceuticals sales through retail pharmacies increased 5% to $386.23
billion in 13 key markets in the 12-month period from November 2005 through to November 2006,
according to IMS Retail Drug Monitor.
Sales figures are at ex-manufacturer prices and include all prescription and certain over-the-counter data.Figures include sales from the hospital sector in Japan and mail order in the USA.
- Sales in the top five European markets showed a 4% constant exchange growth.
- North America posted a 7% sales growth at $209.98 billion in sales in the 12 months to November. The U.S. accounted for $196.2 billion in sales.
- Japan's overall growth was flat at 0% growth in the $56.78 billion market.
Cardiovascular
continues to be the single largest therapeutic category with global sales
of over $75 billio, followed by central nervous system $72.7
billion.
The best selling drug for the 12 months
ending November 2006 was Lipitor, worth over $11.62 billion, with a decreased growth at 3.7%. Nexium still has the largest growth at the top with 16.2%.
The top 5 drugs in the year to November 2006:
1. Lipitor
2. Nexium
3. Seretide
4. Plavix
5. Norvasc
The top 5 corporations in the year to November 2006:
1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. AstraZeneca
5. Merck & Co.
